Inspire's therapy received FDA approval on August 27, 2025, and Rick Buchholz was serving as Chief Financial Officer.
2 reports, 1 independent
Updated Aug 27
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Inspire's therapy received FDA approval on August 27, 2025, and Rick Buchholz was serving as Chief Financial Officer.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Piper Sandler lowered its price target for Inspire after the company released its Q2 2025 financial results.Sub-event
- Inspire initiated the full launch of its neurostimulation system on August 8, 2025.Sub-event
Inspire secured FDA approval for its therapy, with Rick Buchholz as CFO.1 source
Keep exploring
The entities involved
Related events
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA approval expands patient access to therapies for ACCORD.
- Research advances have led to the approval of new therapies by the FDA.
- FDA approved a drug based on UVA research led by Xuemei Huang.
Coverage
Newest first; wire copies grouped- GlobeNewswireInspire Medical Systems, Inc. Announces Departure of Chief Financial Officer MINNEAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology
- GlobeNewswireInspire Medical Systems, Inc. to Present at the Wells Fargo 2025 Healthcare Conference MINNEAPOLIS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical t